PLUS Therapeutics, Inc. (PSTV) is a clinical-stage pharmaceutical company with a focus on innovative oncology drugs. Originally named Cytori Therapeutics, the company changed its name to PLUS Therapeutics, Inc. in 2019. The company's headquarters are based in Austin, Texas.
PLUS Therapeutics is primarily involved in restructuring a clinically advanced, proprietary pipeline of novel therapies to treat a diverse spectrum of cancers. Their mission is to discover, develop and bring to market therapies that will help patients with life-threatening diseases. The company is committed to leveraging its extensive expertise and resources inside and outside oncology to bring forward effective and safe treatments for patients.
The company's core research and development programs are categorized into two series: Rhenium and RASio. The Rhenium program includes a patented nanoparticle-based radiotherapy Rhenium-186 NanoLiposome (186RNL) product candidate, which is currently in Phase 1 clinical trial for recurrent glioblastoma, a lethal brain cancer. The RASio program aims to inhibit the RAS signaling pathway, responsible for many types of cancer.
What sets PLUS Therapeutics apart is their pioneering approach to drug development. They reuse known drugs in a novel manner, reformulating them into new, patented medicine. The primary advantage is the lower development costs and the possibility to fast-track the product to the market due to the known safety profile of the active ingredients of the base drug.
Financially, PLUS Therapeutics, Inc. is categorized under the ticker PSTV in the NASDAQ stock exchange. As a public company, they are dedicated to creating shareholder's value through the aggressive advancement of their clinical programs and the opportune leverage of their intellectual property.
In summary, PLUS Therapeutics, Inc. is a trailblazer in the pharmaceutical industry by setting out to make a significant difference in patients' lives through the development and commercialization of targeted cancer treatments. Their pursuit of life-changing cancer treatments and commitment to patients' welfare, combined with innovative research and development, makes them an essential player in the global healthcare industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Plus Therapeutics has amended its bylaws to reflect a corporate name change to Cerenome, effective August 3, 2026. The company's Nasdaq trading symbol also switched to CNSY on the same date, though the CUSIP for the common stock remains unchanged. This news brief was generated by AI, based on original content filed by Plus Therapeutics Inc. with the SEC.
Plus Therapeutics has rebranded as Cerenome, a move that signifies its evolution into an integrated central nervous system (CNS) oncology company. Cerenome will focus on three key pillars: CNSide, a diagnostic platform for CNS cancers; Reyobiq, an investigational targeted radiotherapeutic; and a proprietary data analytics and AI platform for precision oncology. This rebranding reflects the company's commitment to advancing CNS cancer treatment through a comprehensive approach.
Plus Therapeutics is rebranding to Cerenome, effective August 3, 2026, and will trade under the new Nasdaq ticker CNSY. This strategic shift transforms the company from a therapeutics-focused entity into an integrated CNS oncology company, combining precision diagnostics, targeted therapeutics, and AI to improve patient outcomes for central nervous system cancers. Cerenome's lead product, REYOBIQ™, is currently in clinical trials for various brain cancers, aiming to deliver targeted radiation with minimal systemic exposure.
Plus Therapeutics, Inc. announced its participation in the 2026 SNO/ASCO CNS Metastases Conference, where it will present two posters on its ReSPECT-LM clinical program and CNSide® diagnostic platform. The company, along with its subsidiary CNSide Diagnostics, will also host a symposium titled "Redefining the Management of Leptomeningeal Metastases." This event will highlight their integrated approach to CNS cancers, featuring discussions on diagnostics, molecular insights, and emerging therapies.
Plus Therapeutics (PSTV) is set to present new research at the 2026 SNO/ASCO CNS Metastases Conference, focusing on their ReSPECT-LM clinical development program and introducing their new brand, Cerenome. The company will also host a symposium on leptomeningeal metastases management and provide updates on their REYOBIQ™ radiotherapy. These initiatives aim to advance CNS cancer treatment, enhance market recognition, and attract investor interest.
Plus Therapeutics, Inc. will present two posters and host a sponsored symposium at the 2026 SNO/ASCO CNS Metastases Conference. The presentations will highlight the Company's REYOBIQ™ clinical development program and CNSide® cerebrospinal fluid diagnostic platform, focusing on improving detection, characterization, treatment, and monitoring of CNS metastases. Additionally, Plus Therapeutics will formally introduce its new corporate identity, Cerenome, and new branding related to its expanded focus on CNS cancer.